Abstract: An N-ethyl hydroxyethyleneamine of formula (I) are disclosed which are useful in treating CNS conditions, including neurodegenerative diseases such as Alzheimer's Disease.

Abstract: The present invention relates to compounds of the formula (I) their isomer, prodrugs of these compounds or isomers, or a pharmaceutically acceptable salts of these compounds, isomers or prodrugs; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and X are defined as in the specification, to pharmaceutical compositions containing them and methods of using these compounds, their isomer, prodrugs of these compounds or isomers, or a pharmaceutically acceptable salts of these compounds, isomers or prodrugs to treat obesity, diabetes, anxiety, or inflammatory diseases or for modulating a process mediated by GR in mammals.

Abstract: The present invention relates to compounds of Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of Formula I.

Abstract: The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1—R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.